Skip to main content
x

Recent articles

Genor goes one better

Can activity at CTLA-4 be added to PD-1 x VEGF blockade?

Another Roche TIGIT disappointment

Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.

ASCO 2025 preview – late-breakers in focus

The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.

Lilly urges degrader caution

Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

Ivo combo beats Tevimbra, but can it beat Keytruda?

The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.

Trodelvy gets one up on Datroway in triple-negative breast

Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.